Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain

Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.

Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.

Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.

Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.

Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.

Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.